APPLICATION OF POLYVINYLPYRROLIDONE K30 AND CHITOSAN AS CO-BINDERS IN PREPARING FUROSEMIDE TABLET BY WET GRANULATION METHOD

Main Article Content

Pienkit Dangprasirt
Sansanee Pongwai
Vasinee Limwong
Saraporn Harigarnpakdi
Kanokporn Burapapat
Moleephan Dangprasirt

Abstract

Furosemide tablets were prepared by wet granulation using polyvinylpyrrolidone K 30 (PVP) alone, as single binder, and PVP with chitosan (CS), as co-binders. Spray-dried rice starch (Era-Tab®) and croscarmellose sodium (Ac-Di-Sol®) were employed as tablet diluent and disintegrant, respectively. The prepared tablets were tested for tablet physical properties, disintegration and dissolution. The effects of PVP, CS and Ac-Di-Sol® contents on tablet friability, disintegration time and dissolution were studied using a two-level full factorial experimental design. The tested properties of furosemide tablets prepared by using the single binder were compared to those prepared by using the co-binders. The usage of co-binders, PVP and CS, was found to significantly decrease the tablet friability without considerable change in disintegration time. The furosemide tablet of good physical properties and fast drug dissolution was prepared by using low content of Ac-Di-Sol® and optimum amounts of the co-binders, PVP and CS. Inclusion of a surfactant, sodium lauryl sulfate (SLS), in the furosemide tablets did not improve the tablet dissolution. No significant change in tablet dissolution profile was observed when sodium starch glycolate (Explotab®) was used as disintegrant, instead of Ac-Di-Sol®, in the furosemide tablets prepared by using co-binders. However, the usage of proper content of SLS in the furosemide tablet formulation consisting of Explotab® was found to provide the tablet of improved dissolution. 

Article Details

How to Cite
1.
Dangprasirt P, Pongwai S, Limwong V, Harigarnpakdi S, Burapapat K, Dangprasirt M. APPLICATION OF POLYVINYLPYRROLIDONE K30 AND CHITOSAN AS CO-BINDERS IN PREPARING FUROSEMIDE TABLET BY WET GRANULATION METHOD. Interprof J Health Sci [Internet]. 2023 Oct. 5 [cited 2024 Dec. 6];12(1):33-4. Available from: https://li05.tci-thaijo.org/index.php/IJHS/article/view/92
Section
Research Articles

References

Allen LV, Popovich NG, Ansel, HC. 2011. Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems. 9th ed. Philadelphia: Lippincott Williams & Wilkins.

Bandelin FJ. 1989. Compressed tablets by wet granulation. In: Lieberman HA, Lachman L, Schwartz JB, editors. Pharmaceutical Dosage Forms. Tablets. Volume 1. 2nd ed. New York: Marcel Dekker; 149-150.

Brine CJ. 1989. Controlled release pharmaceutical applications of chitosan. In: Gudmund Skjak-Braek G, Anthonsen T, Sandford P, editors. Chitin and chitosan: sources, chemistry, biochemistry, physical properties, and applications. London: Elsevier Science; pp. 679-691.

Florence AT. 1981. Drug solubilization in surfactant systems. In: Yalkowsky SH. editor. Techniques of Solubilization of Drugs. New York: Marcel Dekker; pp. 60-63.

Kepsutlu AR, Savaser A, Ozkan Y, Dikmen N, Isimer A. 1999. Evaluation of chitosan as an excipient in tablet formulations. Acta Poloniae Pharmaceutica-Drug Research. 56(3): 227-235.

Rinaudo M. 2006. Chitin and chitosan: Properties and applications. Prog Poly. Sci. 31: 603-632

Rowe RC, Sheskey, PJ, Quinn., ME. 2009. Handbook of Pharmaceutical Excipients. 6th Edition. Chicago: Pharmaceutical Press.

Sandford P. 1989. Chitosan, commercial uses and potential applications. In: Gudmund Skjak-Braek G, Anthonsen T, Sandford P, editors. Chitin and chitosan: sources, chemistry, biochemistry, physical properties, and applications. London: Elsevier Science; pp. 51.

The Department of Health, Great Britain. The Department of Health, Social, Services and Public Safety, Northern Ireland. 2008. British Pharmacopoeia. Volume IV. London: The Stationary Office. Appendix XII C A313.

The United States Pharmacopeia. The National Formulary. 2009. USP 32 and NF 27. Volume 1.1. Volume 2.2. Rockville: The United States Pharmacopeial Convention, Rockville.